Le Lézard
Classified in: Health, Business

Grant Application Deadline Extended to November 15th for Researchers Investigating Causes/Treatments of Job Syndrome


NEW YORK, Sept. 26, 2018 /PRNewswire-PRWeb/ -- The Job Research Foundation has announced that it will extend the deadline for its grant application to November 15th, 2018. Job Research Foundation will award a pair of two-year grants of up to $200,000 each, and a pair of two-year grants of up to $50,000 each to qualified grantees for research into the causes and treatments of the rare multisystem immunodeficiency disorder called Job Syndrome. Special consideration will be given to research focused on Job Syndrome and Pulmonary Function. The application process is open to researchers world-wide through November 15th, 2018 and grants will be awarded by December 17th, 2018.

The Job Research Foundation seeks to not only help find a cure for Job Syndrome by providing the scientific community with additional opportunities to further research into the rare multisystem immunodeficiency disorder, but also hopes that investigators will research treatments for those suffering with Job Syndrome.

Only about 300 cases of Job's Syndrome have been reported since it was first discovered. Patients often suffer from life-threatening complications from basic infections as the disease makes the immune system extremely sensitive to bacteria. People with the syndrome often have multiple, recurring ailments, such as skin infections that cause lesions and boils, and lung infections that cause pneumonia. The disease was named after the Biblical character Job who suffered from boils.

"Our long-term goal is to help advance research to find a cure for Job Syndrome and after several requests we felt it was prudent to extend the deadline to give researchers around the world ample time to submit their application," said Ted Lavin, co-founder of The Job Research Foundation. "In the short term, we hope the research will improve the treatments for patients suffering from this rare disease."

Job Syndrome, also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), was discovered in 1966 and is a multisystem immunodeficiency disorder found in males and females worldwide. It can be inherited from either parent or result from a new genetic mutation.

Visit https://www.jobresearchfoundation.org/ for additional details about The Job Syndrome Foundation and for information about the Grant Application Process. Job Research Foundation is located at 459 Columbus Avenue in New York. Send emails to [email protected].

 

SOURCE Job Research Foundation


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: